Technical Data
T9160-10A
Tumor Necrosis Factor alpha, Recombinant, Human (TNFa)
10ug
50ug
50ug
|
Technical Data |
|
T9160-10A |
Tumor Necrosis Factor alpha, Recombinant, Human (TNFa) |
10ug 50ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
TNF is secreted by macrophages, monocytes, neutrophils, T-cells, NK-cells following their stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-alpha while CD8 cells secrete little or no TNF-alpha. The synthesis of TNF-alpha is induced by many different stimuli including interferons, IL2, GM-CSF. Recombinant Human Tumor Necrosis Factor-alpha is a single, non-glycosylated, polypeptide chain containing 158 amino acids and having a molecular mass of 17483.77 Dalton. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Met-Val-Arg-Ser-Ser. Dimers and Aggregates: 1% as determined by silver-stained SDS-PAGE gel analysis. Biological Activity: Recombinant Tumor Necrosis Factor-alpha is fully biologically active when compared to standard. The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D is less then 0.05ng/ml, corresponding to a Specific Activity of 2 x 10e7 IU/mg. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280 nm using the absorbency value of 1.24 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of TNF-alpha as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile ddH2O, 0.1% HSA or BSA and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: Recombinant, Human (E. coli) Purity: 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: <0.1ng/ug (IEU/ug). Concentration: ~0.1mg/ml Form: Supplied as a liquid in 20mM PBS, pH 7.2, 0.1% BSA. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Early appearance of TNF-alpha and other cytokines in bronchus associated lymphoid tissues (BALT) from growing Wistar rats. what is the role of TNF-alpha? Delettieres D, Frecha CA, Clin Dev Immunol 2004 Sep-Dec;11(3-4):253-9 2. A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. Campbell J, Ciesielski CJ, Horwood NJ, Feldmann M, J Immunol 2004 Dec 1;173(11):6928-37 3. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. Gertsch J, Schoop R, Suter A, FEBS Lett 2004 Nov 19;577(3):563-9 4. Expression and regulation of neuropilins and VEGF receptors by TNF-alpha in human endothelial cells. Yang H, Li M, Yan S, J Surg Res 2004 Dec;122(2):249-55 5. Implication of delayed TNF-alpha exposure on dendritic cell maturation and expansion from cryopreserved cord blood CD34+ hematopoietic progenitors. Xu RL, Tang Y, Malinowski K, J Immunol Methods 2004 Oct;293(1-2):169-82 6. Release of TNF-alpha from in vitro-stimulated monocytes is negatively associated with serum levels of apolipoprotein B in patients with type 2 diabetes. Zykova SN, Svartberg J, Iversen H, Scand J Immunol 2004 Nov;60(5):535-42.
|
||